EP2739139A4 - Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same - Google Patents
Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the sameInfo
- Publication number
- EP2739139A4 EP2739139A4 EP12819260.6A EP12819260A EP2739139A4 EP 2739139 A4 EP2739139 A4 EP 2739139A4 EP 12819260 A EP12819260 A EP 12819260A EP 2739139 A4 EP2739139 A4 EP 2739139A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- agonists
- same
- treatment methods
- protein tyrosine
- containing protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710204865 Tyrosine-protein phosphatase 1 Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/08—Oxygen or sulfur directly attached to an aromatic ring system
- A01N31/14—Ethers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds containing nitrogen-to-oxygen bonds
- A01N33/18—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Dentistry (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL12819260T PL2739139T3 (en) | 2011-08-03 | 2012-08-03 | Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161514555P | 2011-08-03 | 2011-08-03 | |
PCT/US2012/049446 WO2013020014A1 (en) | 2011-08-03 | 2012-08-03 | Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2739139A1 EP2739139A1 (en) | 2014-06-11 |
EP2739139A4 true EP2739139A4 (en) | 2015-06-10 |
EP2739139B1 EP2739139B1 (en) | 2019-09-25 |
Family
ID=47629697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12819260.6A Active EP2739139B1 (en) | 2011-08-03 | 2012-08-03 | Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
Country Status (18)
Country | Link |
---|---|
US (1) | US9216950B2 (en) |
EP (1) | EP2739139B1 (en) |
JP (1) | JP2014527043A (en) |
KR (1) | KR101661825B1 (en) |
CN (1) | CN104010501B (en) |
AU (1) | AU2012289961C1 (en) |
BR (1) | BR112014002363A2 (en) |
CA (1) | CA2843330C (en) |
ES (1) | ES2762193T3 (en) |
IL (1) | IL230601A (en) |
IN (1) | IN2014MN00125A (en) |
MX (1) | MX353205B (en) |
MY (1) | MY175797A (en) |
PL (1) | PL2739139T3 (en) |
RU (1) | RU2584986C2 (en) |
TW (1) | TWI507191B (en) |
WO (1) | WO2013020014A1 (en) |
ZA (1) | ZA201400757B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2890380A2 (en) * | 2012-08-29 | 2015-07-08 | Merck Patent GmbH | Ddr2 inhibitors for the treatment of osteoarthritis |
JP6489658B2 (en) * | 2013-04-25 | 2019-03-27 | シービーエス バイオサイエンス,カンパニー,リミテッド | Analytical method for increasing the sensitivity of molecular targeted therapy in hepatocellular carcinoma |
WO2015051149A1 (en) * | 2013-10-04 | 2015-04-09 | The Trustees Of Columbia University In The City Of New York | Sorafenib analogs and uses thereof |
AU2016316223A1 (en) * | 2015-08-31 | 2018-02-22 | Toray Industries, Inc. | Urea derivative and use therefor |
WO2017036405A1 (en) * | 2015-09-02 | 2017-03-09 | 陈昆锋 | Compound having protein tyrosine phosphatase shp-1 agonist activity |
WO2018035346A1 (en) * | 2016-08-17 | 2018-02-22 | Ichan School Of Medicine At Mount Sinal | Kinase inhibitor compounds, compositions, and methods of treating cancer |
US10993923B2 (en) | 2016-09-22 | 2021-05-04 | Kuen-Feng Chen | Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea |
CN110461322A (en) * | 2017-02-03 | 2019-11-15 | 加利福尼亚大学董事会 | For inhibiting the composition and method of plasma membrane protein 4 |
CN113402456B (en) * | 2020-03-16 | 2023-03-03 | 深圳大学 | Antitumor drug and application of compound or pharmaceutically acceptable salt thereof in antitumor drug |
CN112084184B (en) * | 2020-09-15 | 2022-12-16 | 青海省地质测绘地理信息院 | Method for transmitting heterogeneous data attributes between different GIS platforms |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005102997A1 (en) * | 2004-04-26 | 2005-11-03 | Astrazeneca Ab | 3,4-disubstituted maleimides for use as vascular damaging agents |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1241832B (en) * | 1963-02-23 | 1967-06-08 | Hoechst Ag | Process for the preparation of pyrimidinium compounds |
IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
WO1993015043A1 (en) * | 1992-01-24 | 1993-08-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Arylalkananilide compound and pharmaceutical use thereof |
ES2129123T3 (en) * | 1993-04-30 | 1999-06-01 | Yamanouchi Pharma Co Ltd | NEW DERIVATIVE OF BISOXADIAZOLIDINE. |
IL136690A0 (en) * | 1997-12-22 | 2001-06-14 | Bayer Ag | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
DE60039115D1 (en) * | 1999-08-20 | 2008-07-17 | Dow Agrosciences Llc | FUNGICIDES HETEROCYCLIC AROMATIC AMIDS AND THEIR COMPOSITIONS, METHODS OF THEIR APPLICATION AND MANUFACTURE |
DE19954312A1 (en) * | 1999-11-11 | 2001-05-17 | Bayer Ag | Substituted phenyluracile |
JP4529119B2 (en) * | 2001-08-09 | 2010-08-25 | 小野薬品工業株式会社 | Carboxylic acid derivative compound and drug containing the compound as an active ingredient |
SE0401969D0 (en) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidine derivatives |
US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
EP2519517B1 (en) * | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
WO2012112570A1 (en) | 2011-02-14 | 2012-08-23 | The Regents Of The University Of California | SORAFENIB DERIVATIVES AS sEH INHIBITORS |
-
2012
- 2012-08-03 TW TW101128133A patent/TWI507191B/en active
- 2012-08-03 EP EP12819260.6A patent/EP2739139B1/en active Active
- 2012-08-03 AU AU2012289961A patent/AU2012289961C1/en active Active
- 2012-08-03 PL PL12819260T patent/PL2739139T3/en unknown
- 2012-08-03 JP JP2014523113A patent/JP2014527043A/en active Pending
- 2012-08-03 MY MYPI2014700189A patent/MY175797A/en unknown
- 2012-08-03 WO PCT/US2012/049446 patent/WO2013020014A1/en active Application Filing
- 2012-08-03 KR KR1020147003923A patent/KR101661825B1/en active IP Right Grant
- 2012-08-03 RU RU2014101953/04A patent/RU2584986C2/en active
- 2012-08-03 CN CN201280038359.7A patent/CN104010501B/en active Active
- 2012-08-03 ES ES12819260T patent/ES2762193T3/en active Active
- 2012-08-03 IN IN125MUN2014 patent/IN2014MN00125A/en unknown
- 2012-08-03 CA CA2843330A patent/CA2843330C/en active Active
- 2012-08-03 US US14/235,620 patent/US9216950B2/en active Active
- 2012-08-03 MX MX2014001157A patent/MX353205B/en active IP Right Grant
- 2012-08-03 BR BR112014002363-8A patent/BR112014002363A2/en not_active IP Right Cessation
-
2014
- 2014-01-22 IL IL230601A patent/IL230601A/en active IP Right Grant
- 2014-01-31 ZA ZA2014/00757A patent/ZA201400757B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005102997A1 (en) * | 2004-04-26 | 2005-11-03 | Astrazeneca Ab | 3,4-disubstituted maleimides for use as vascular damaging agents |
Non-Patent Citations (4)
Title |
---|
K.-F. CHEN ET AL: "Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3", CLINICAL CANCER RESEARCH, vol. 16, no. 21, 30 September 2010 (2010-09-30), pages 5189 - 5199, XP055156100, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-3389 * |
KUEN-FENG CHEN ET AL: "Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 7, 1 July 2011 (2011-07-01), pages 2845 - 2851, XP055141910, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2011.04.007 * |
See also references of WO2013020014A1 * |
WEI-TIEN TAI ET AL: "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 55, no. 5, 25 January 2011 (2011-01-25), pages 1041 - 1048, XP028319540, ISSN: 0168-8278, [retrieved on 20110224], DOI: 10.1016/J.JHEP.2011.01.047 * |
Also Published As
Publication number | Publication date |
---|---|
KR101661825B1 (en) | 2016-09-30 |
AU2012289961C1 (en) | 2016-09-01 |
US20140200239A1 (en) | 2014-07-17 |
BR112014002363A2 (en) | 2017-06-13 |
CA2843330A1 (en) | 2013-02-07 |
RU2584986C2 (en) | 2016-05-27 |
IN2014MN00125A (en) | 2015-06-12 |
IL230601A (en) | 2017-07-31 |
RU2014101953A (en) | 2015-09-10 |
TW201320997A (en) | 2013-06-01 |
AU2012289961A1 (en) | 2014-02-20 |
MY175797A (en) | 2020-07-09 |
CN104010501B (en) | 2016-05-04 |
ZA201400757B (en) | 2015-10-28 |
PL2739139T3 (en) | 2020-06-15 |
IL230601A0 (en) | 2014-03-31 |
WO2013020014A1 (en) | 2013-02-07 |
EP2739139B1 (en) | 2019-09-25 |
CA2843330C (en) | 2016-09-20 |
KR20140039331A (en) | 2014-04-01 |
US9216950B2 (en) | 2015-12-22 |
NZ620434A (en) | 2015-08-28 |
AU2012289961B2 (en) | 2016-05-19 |
MX2014001157A (en) | 2015-02-04 |
CN104010501A (en) | 2014-08-27 |
JP2014527043A (en) | 2014-10-09 |
MX353205B (en) | 2018-01-08 |
ES2762193T3 (en) | 2020-05-22 |
EP2739139A1 (en) | 2014-06-11 |
TWI507191B (en) | 2015-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201400757B (en) | Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same | |
IL261768B (en) | Devices and methods for the treatment of tissue | |
IL261151A (en) | Water soluble membrane proteins and methods for the prepartion and use thereof | |
IL245042A0 (en) | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy | |
HK1221953A1 (en) | Protein tyrosine kinase modulators and methods of use | |
HUE053720T2 (en) | Therapeutic antibodies against ror-1 protein and methods for use of same | |
HK1211030A1 (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same iap | |
EP3062825A4 (en) | Near-infrared fluorescent contrast bioimaging agents and methods of use thereof | |
EP2590982A4 (en) | Protein kinase inhibitors and methods of treatment | |
LT3040424T (en) | Modified proteins and methods of making and using same | |
HK1197187A1 (en) | Anti-lrp5 antibodies and methods of use lrp5 | |
EP2782589A4 (en) | Anti-microbial peptides and methods of use thereof | |
EP2802362A4 (en) | Liquid gel concentrate compositions and methods of use | |
EP2579870A4 (en) | Trkb agonists and methods of use | |
HK1260897A1 (en) | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity | |
HK1194308A1 (en) | Methods and use of bifunctional enzyme-building clamp-shaped molecules | |
ZA201305266B (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
IL243535A0 (en) | Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof | |
IL227816A0 (en) | Peptide library, constructs comprising the same and methods of use of the same | |
EP2753359A4 (en) | Serpinf2-binding molecules and methods of use | |
IL239078A0 (en) | Protein for use in the treatment of ocular diseases | |
IL234492A (en) | Crystal forms of 5α-androstane-3β,5,6β-triol and preparation methods therefor | |
EP2911640A4 (en) | Sample holders and methods of using them | |
EP2956469A4 (en) | Methods and compositions for protein concentration | |
GB2501855B (en) | Sample Capture System and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140128 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 215/40 20060101ALI20141210BHEP Ipc: C07C 275/36 20060101ALI20141210BHEP Ipc: C07D 215/233 20060101ALI20141210BHEP Ipc: A61K 31/075 20060101AFI20141210BHEP Ipc: C07C 255/54 20060101ALI20141210BHEP Ipc: C07D 213/81 20060101ALI20141210BHEP |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150512 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07C 255/54 20060101ALI20150506BHEP Ipc: A61K 31/075 20060101AFI20150506BHEP Ipc: C07D 215/233 20060101ALI20150506BHEP Ipc: C07D 213/81 20060101ALI20150506BHEP Ipc: C07D 215/40 20060101ALI20150506BHEP Ipc: C07C 275/36 20060101ALI20150506BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170717 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NATIONAL TAIWAN UNIVERSITY Owner name: NATIONAL YANG-MING UNIVERSITY |
|
INTG | Intention to grant announced |
Effective date: 20190410 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012064359 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1183128 Country of ref document: AT Kind code of ref document: T Effective date: 20191015 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KAMINSKI HARMANN PATENTANWAELTE AG, LI |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191225 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191225 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191226 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200127 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2762193 Country of ref document: ES Kind code of ref document: T3 Effective date: 20200522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012064359 Country of ref document: DE |
|
PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200126 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20200626 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200803 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1183128 Country of ref document: AT Kind code of ref document: T Effective date: 20190925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190925 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230823 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230731 Year of fee payment: 12 Ref country code: IT Payment date: 20230831 Year of fee payment: 12 Ref country code: GB Payment date: 20230824 Year of fee payment: 12 Ref country code: ES Payment date: 20230918 Year of fee payment: 12 Ref country code: CZ Payment date: 20230724 Year of fee payment: 12 Ref country code: CH Payment date: 20230902 Year of fee payment: 12 Ref country code: AT Payment date: 20230818 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230823 Year of fee payment: 12 Ref country code: PL Payment date: 20230724 Year of fee payment: 12 Ref country code: FR Payment date: 20230821 Year of fee payment: 12 Ref country code: DE Payment date: 20230831 Year of fee payment: 12 Ref country code: BE Payment date: 20230822 Year of fee payment: 12 |